MedTrace Logo

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

NCT06769984 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-01-10

No results posted yet for this study

Summary

Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease

Conditions

  • TED

Interventions

DRUG

SCTT11

SCTT11 dose 1, dose 2, dose 3, dose 4

DRUG

Placebo

Placebo dose 1, dose 2, dose 3, dose 4

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2026-06-24
Completion
2028-09-19

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06769984 on ClinicalTrials.gov